Drug Type TCR-T Cell therapy |
Synonyms HRYZ T101, HRYZ-T101, HRYZT101 |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Vagina Carcinoma | Phase 1 | China | 01 Nov 2023 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 21 Mar 2023 | |
| Anus Neoplasms | Phase 1 | China | 21 Mar 2023 | |
| HPV18 positive solid tumors | Phase 1 | China | 21 Mar 2023 | |
| Oropharyngeal Neoplasms | Phase 1 | China | 21 Mar 2023 | |
| Penile Neoplasms | Phase 1 | China | 21 Mar 2023 | |
| Squamous Cell Carcinoma of Head and Neck | Phase 1 | China | 21 Mar 2023 | |
| Uterine Cervical Cancer | Phase 1 | China | 21 Mar 2023 | |
| Vulvar Neoplasms | Phase 1 | China | 21 Mar 2023 |





